Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$45.38 USD

45.38
37,372,119

-1.84 (-3.90%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $45.50 +0.12 (0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (90 out of 246)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Kinjel Shah headshot

How Should You Play Pfizer (PFE) After COVID-Flu Shot Setback?

by Kinjel Shah

After Pfizer's (PFE) better-than-expected second-quarter results and the bullish outlook for the year, investors who own Pfizer's stock may consider staying invested.

Kinjel Shah headshot

Is Eli Lilly (LLY) a Buy Post Stellar Q2 Earnings & Raised View?

by Kinjel Shah

Eli Lilly (LLY) is a great stock to have in one's portfolio currently based on its strong overall financial performance and robust drug pipeline.

Zacks Equity Research

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock

by Zacks Equity Research

Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Ahan Chakraborty headshot

Here's How to Play Novo Nordisk (NVO) After Q2 Earnings Miss

by Ahan Chakraborty

Novo Nordisk (NVO) is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs. New investors should utilize the existing opportunity to make an entry.

Zacks Equity Research

Why Novo Nordisk (NVO) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Shaun Pruitt headshot

Should Investors Buy Eli Lilly's (LLY) Stock After Strong Q2 Results?

by Shaun Pruitt

As one of the largest pharmaceutical companies, Eli Lilly (LLY) said its growth trajectory accelerated during Q2 as its medicines are reaching more people worldwide.

Zacks Equity Research

Is Novo Nordisk (NVO) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Novo Nordisk (NVO) could produce exceptional returns because of its solid growth attributes.

Zacks Equity Research

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Novo Nordisk (NVO) have performed compared to their sector so far this year.

Zacks Equity Research

Is It Worth Investing in Novo Nordisk (NVO) Based on Wall Street's Bullish Views?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Novo Nordisk (NVO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Kinjel Shah headshot

Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates

by Kinjel Shah

Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.

Zacks Equity Research

Prothena (PRTA) Q2 Earnings Benefit From Collaboration Revenues

by Zacks Equity Research

Prothena (PRTA) records impressive second-quarter earnings as the top line benefits from a $80-million payment from collaboration partner BMY.

Zacks Equity Research

Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day

Ethan Feller headshot

Eli Lilly: The Next $1 Trillion Market Cap Stock?

by Ethan Feller

Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning

Zacks Equity Research

Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View

by Zacks Equity Research

Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.

Zacks Equity Research

Company News for Aug 8, 2024

by Zacks Equity Research

Companies In The Article Are:SHOP, SUN, CIM,NVO

Zacks Equity Research

Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.

Zacks Equity Research

Novo Nordisk (NVO) Falls as Q2 Earnings and Sales Miss, View Up

by Zacks Equity Research

Novo Nordisk (NVO) falls as it reports lower-than-expected Q2 results, missing both earnings and revenue estimates. However, sales of Diabetes and Obesity care products increase year over year.

Derek Lewis headshot

Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look

by Derek Lewis

Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.

Zacks Equity Research

Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

Kanishka Das headshot

Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?

by Kanishka Das

Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.

Kinjel Shah headshot

Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?

by Kinjel Shah

Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.

Zacks Equity Research

PFE vs. NVO: Which Stock Is the Better Value Option?

by Zacks Equity Research

PFE vs. NVO: Which Stock Is the Better Value Option?

Zacks Equity Research

TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up

by Zacks Equity Research

TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.

Zacks Equity Research

Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Novo Nordisk (NVO) concluded the recent trading session at $128.05, signifying a +1.04% move from its prior day's close.

Zacks Equity Research

Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.